Page 2 - Omp360 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Omp360. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Omp360 Today - Breaking & Trending Today

COMPASS Pathfinder Ltd.: COMPASS Pathways and Kings College London publish cognition results from COMP360 psilocybin study in healthy volunteers


(0)
LONDON, June 03, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS) ( COMPASS ), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has reported further results from a phase I study showing that its COMP360 psilocybin had no clinically-relevant negative effect on cognitive function, when administered to healthy adult volunteers with support from specially trained therapists.
The data) from the randomised, double-blind, placebo-controlled, phase I trial conducted at King s College London, will be presented today at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, by Dr James Rucker, Consultant Psychiatrist and Senior Clinical Lecturer in Psychopharmacology at King s College London s Institute of Psychiatry, Psychology and Neuroscience (IoPPN). Initial results from the study were published in December 2019. The results published today present a more in-depth analysis of c ....

United States , United Kingdom , City Of , Ekaterina Malievskaia , James Rucker , Tracy Cheung , Stephen Schultz , King College London , Exchange Commission , American Society Of Clinical Psychopharmacology , Institute Of Psychiatry , Qs World University Rankings , College London , American Society , Clinical Psychopharmacology , Annual Meeting , Consultant Psychiatrist , Senior Clinical Lecturer , Chief Innovation Officer , University Rankings , Securities Act , Private Securities Litigation Reform Act , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , நகரம் ஆஃப் , ஜேம்ஸ் ரக்கர் ,

COMPASS Pathfinder Ltd.: New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder


(0)
Study concludes that psilocybin findings should be explored further in larger studies
London, UK, April 15, 2021(NEJM) yesterday, which showed signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram, for major depressive disorder (MDD).
The study was designed and conducted by a research team at Imperial College London, using COMPASS s COMP360 psilocybin.
This was an exploratory, randomised, double-blind clinical study. Its aim was to compare the efficacy and mechanisms of action of psilocybin with a six-week course of escitalopram, a selective serotonin reuptake inhibitor (SSRI), for MDD.
The study included 59 participants; 30 were randomly assigned to the psilocybin arm, and 29 to the escitalopram arm. Participants in the psilocybin arm received two doses of 25mg psilocybin three weeks apart, with psychological support delivered prior to, during and after each psilocybin administration, plus six weeks of ....

New York , United States , United Kingdom , City Of , Kostenloser Wertpapierhandel , Tracy Cheung , George Goldsmith , Stephen Schultz , Exchange Commission , Imperial College London , Drug Administration , Quick Inventory , Depressive Symptomatology , Montgomery Asberg Depression Rating Scale , Hamilton Depression Rating Scale , Serious Adverse Events , Breakthrough Therapy , Securities Act , Private Securities Litigation Reform Act , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , நகரம் ஆஃப் , சுவடு செயுங் , ஜார்ஜ் பொற்கொல்லர் , ஸ்டீபன் ஶுல்ட்ஸ் ,